Clinical Trial Update: IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment [Phase 3]

View source ↗

Summary

Phase 3 trial update for IBI112 in moderate-to-severe plaque psoriasis, involving randomized withdrawal and re-treatment; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• IBI112

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Psoriasis | Phase 3 | Status: COMPLETED